Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
A Mini-Review on Sofosbuvir and Daclatasvir Treatment in Coronavirus Disease 2019 Publisher



Shabani M1 ; Sadegh Ehdaei B2 ; Fathi F3 ; Dowran R1
Authors

Source: New Microbes and New Infections Published:2021


Abstract

Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between hepatitis C virus RNA polymerase and severe acute respiratory syndrome coronavirus 2 has also been established. The efficacy of sofosbuvir and daclatasvir as potential choices in treating patients with coronavirus disease 2019 and their recovery can be hypothesized. © 2021 The Authors
Related Docs
View other Related Docs
1. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline, Hepatitis Monthly (2016)
2. Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost, Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase Iii Clinical Trial, Clinical Infectious Diseases (2020)
3. Sars-Cov-2: From the Pathogenesis to Potential Anti-Viral Treatments, Biomedicine and Pharmacotherapy (2021)
Experts (# of related papers)
View all Related Experts
Reza Malekzadeh (5)
Hossein Poustchi (5)
Other Related Docs
4. Existing Antiviral Options Against Sars-Cov-2 Replication in Covid-19 Patients, Future Microbiology (2020)
5. Hepatitis C, Influence of Nutrients# Bioactive Compounds# and Plant Extracts in Liver Diseases (2020)
6. The Efficacy of 12Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients With Cirrhosis, Genotypes 1 and 3, Hepatitis Monthly (2017)
7. Antiviral Therapy Inmanagement of Covid-19: A Systematic Review on Current Evidence, Archives of Academic Emergency Medicine (2020)
8. Efficacy of Direct Acting Antivirals (Daa) Therapy in Patients With Recurrent Hepatitis C After Liver and Kidney Transplantation: A Cross-Sectional Study, Frontiers in Medicine (2024)
9. Sofosbuvir/Daclatasvir Regimens for the Treatment of Covid-19: An Individual Patient Data Meta-Analysis, Journal of Antimicrobial Chemotherapy (2021)
10. The Impact of Sofosbuvir/Daclatasvir or Ribavirin in Patients With Severe Covid-19, Journal of Antimicrobial Chemotherapy (2020)
11. Sofosbuvir As a Potential Option for the Treatment of Covid-19, Acta Biomedica (2020)
12. Forced Degradation and Stability Indicating Chromatographic Methods for the Analysis of Sofosbuvir Alone and in Combination With Velpatasvir, Daclatasvir, Voxilaprevir and Ledipasvir, Fabad Journal of Pharmaceutical Sciences (2025)
13. Efficacy of Locally Manufactured Sofosbuvir and Daclatasvir (Sovodak) in Combination With Ribavirin in Treating Patients With Chronic Hepatitis C and Cirrhosis in Iran - Preliminary Report, Govaresh (2016)
14. Safely Treating Hepatitis C in Patients With Hiv or Hepatitis B Virus Coinfection, Expert Opinion on Drug Safety (2015)
15. A Theoretical Strategy for Acceleration of Human Immune Response Against Sars-Cov-2: A Fusion Protein Harboring Virus-Binding and Pre-Exposed Antigen Domains, VirusDisease (2021)
16. Evaluation of the Effect of Sofosbuvir and Daclatasvir in Hospitalized Covid-19 Patients: A Randomized Double-Blind Clinical Trial (Discover), Journal of Antimicrobial Chemotherapy (2022)
17. Erratum: Sd1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-Cost Fixed-Dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter Phase Iii Clinical Trial (Clin Infect Dis (2020) 70:10 (2206-2212) Doi: 10.1093/Cid/Ciz628), Clinical Infectious Diseases (2021)
18. Potential Nephrotoxicity of Sofosbuvir-Based Treatment in Patients Infected With Hepatitis C Virus: A Review on Incidence, Type and Risk Factors, Expert Review of Clinical Pharmacology (2018)
19. Evaluation of the Efficacy of Sofosbuvir Plus Daclatasvir in Combination With Ribavirin for Hospitalized Covid-19 Patients With Moderate Disease Compared With Standard Care: A Single-Centre, Randomized Controlled Trial, Journal of Antimicrobial Chemotherapy (2020)
20. Remdesivir: A Beacon of Hope From Ebola Virus Disease to Covid-19, Reviews in Medical Virology (2020)